Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer

Oncology

Volumn 69, Issue 5, 2005, Pages 414-420

  Fujitani, Kazumasa ^a,c   Narahara, Hiroyuki ^b,c   Takiuchi, Hiroya ^c,d   Tsujinaka, Toshimasa ^a,c   Satomi, Eriko ^c   Gotoh, Masahiro ^c,d   Hirao, Motohiro ^a,c   Furukawa, Hiroshi ^c   Taguchi, Tetsuo ^c  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c Osaka Gastrointestinal Cancer Chemotherapy Study Group   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Advanced gastric cancer; Combination chemotherapy; Paclitaxel; Pharmacokinetics; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BILIRUBIN; FLUOROPYRIMIDINE DERIVATIVE; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REST; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; OXONIC ACID; PACLITAXEL; PYRIDINES; RISK; STOMACH NEOPLASMS; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 29144489413     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089996     Document Type: Article

References (30)

1. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831.
2. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-548.
3. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-3818.
4. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
5. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-557.
6. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009.
7. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999;57:202-210.
8. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
9. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-197.
10. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JHM, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P: Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECGS). Eur J Cancer 2003;39:1264-1270.
11. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G: Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998;9:307-310.
12. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF: Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-274.
13. Ohtsu A, Boku N, Tamura F, Muro K, Shimda Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-419.
14. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T: Phase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-1137.
15. Garcia AA, Leichman CG, Lenz HJ, Baranda J, Lujan R, Casagrande Y, Leichman L: Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2001;31:275-278.
16. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, Kanz L: Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997;24:S96-S100.
17. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabrai LOM, Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer. Am J Clin Oncol 1999;22:580-586.
18. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999;85:295-301.
19. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C: A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000;83:458-462.
20. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 2002;13:497-503.
21. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-2005.
22. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Mtsumura Y, Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212.
23. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996;74:704-710.
24. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, Monden M: Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil. Oncology 2003;64:176-182.
25. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L: Dosedense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-3361.
26. Loffler TM, Freund W, Lipke J, Hausamen TU: Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 1996;23(suppl 16):32-34.
27. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, Paro G: Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002;41:418-424.
28. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-825.
29. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G: Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer 1997;70:214-220.
30. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.